Searched for
MYRBETRIQ
Pharma and healthcare companies to face continued margin pressure: HDFC SecuritiesThe Indian pharmaceutical and healthcare sector is expected to see moderate revenue growth, with EBITDA margins remaining flat, in the Marc...- Buy, Sell or Hold: Citi keeps a buy on Torrent Pharmaceuticals; Morgan Stanley maintains overweight on Reliance IndustriesBrokerages remain positive on select stocks, with Citigroup maintaining a buy rating on Torrent Pharmaceuticals and Morgan Stanley keeping ...
- Zydus settles US Mirabegron patent dispute with Astellas for $120 millionZydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astel...
- CDMO sector to be key beneficiary of China+1 strategy in pharma: Vishal ManchandaSystematix Group's Vishal Manchanda anticipates Q4 results for pharma companies to align with previous quarters, with high single-digit dom...
- Stocks to buy today: Wipro gets downgraded post Q4 results; Lupin could see over 20% upsideBrokerages are showing caution on specific stocks due to factors impacting earnings visibility. Nuvama downgraded Wipro to "Hold," citing w...
- Lupin rallies 4% after multiple approvals from USFDAIn a regulatory filing, the company said it has received approval from the USFDA for mirabegron extended-release tablets.
- Stocks in the news: Here Moto, Indian Oil, Lupin, PNB and Adani Group stocksHero MotoCorp, the two-wheeler manufacturer, said it will invest $60 million in US-based Zero motorcycles to jointly develop electric motor...
- Zydus Cadila gets tentative USFDA nod for overactive bladder treatment drugThe product will be manufactured at the group's manufacturing facility at SEZ in Ahmedabad.
Load More